Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis

Non-alcoholic steatohepatitis (NASH) is a rising health challenge, with no approved drugs. We used a computational drug repositioning strategy to uncover a novel therapy for NASH, identifying a GABA-B receptor agonist, AZD3355 (Lesogaberan) previously evaluated as a therapy for esophageal reflux. AZ...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharya, Dipankar, Becker, Christine, Readhead, Benjamin, Goossens, Nicolas, Novik, Jacqueline, Fiel, Maria Isabel, Cousens, Leslie P., Magnusson, Björn, Backmark, Anna, Hicks, Ryan, Dudley, Joel T., Friedman, Scott L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531016/
https://www.ncbi.nlm.nih.gov/pubmed/34675338
http://dx.doi.org/10.1038/s41598-021-99008-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531016/
https://www.ncbi.nlm.nih.gov/pubmed/34675338
http://dx.doi.org/10.1038/s41598-021-99008-2

Ejemplares similares